‹ ›
MYP_148667
← PREVIOUS NEXT → BACK
Basic Information
RC-101
Antimicrobial
Antimicrobial ▸ Antibacterial
Antiviral
Antiviral ▸ Anti-Herpesvirus ▸ Anti-HSV
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral replication inhibition ▸ Replication inhibitor
Standard
18 amino acids
C74H136N28O19S6
Standard
Sequence
GICRCICGKGICRCICGR
Physicochemical Analysis
1914.44 Da
8.98
3.70
3.41
0.2055
0.78
0.57
0.01
-9.42
86.67
0.0000
0.00
375.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
769.74
-9.15
35.0
29.0
65.0
127.0
0.0
17.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0392331 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
disulfide-constrained cyclic peptide [Cyclic]
canonical L-amino-acid peptide [L]
None
None
3-16, 5-14, 7-12
Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.
Bio-Activity Profile
Antiviral Anti-HIV-1 Entry inhibition
HIV-1 5157-1326 | JC53-BL cells
3.6 μg/mL
IC50
Mammalian: 30 h; Yeast: >20 h; E. coli: >10 h
PaperRC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. | Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI. | AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65. | DOI:10.1089/aid.2004.20.1157 | PMID:15588337 PMID15588337 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15588337/
RECORD: Rec_0393429 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
head-to-tail cyclic peptide [Cyclic]
noncanonical stereochemical modification [Modified]
Bio-Activity Profile
Antimicrobial Antiviral
RC-101 was well tolerated by host tissues
PaperRC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. PMID21825301 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21825301/
RECORD: Rec_0420643 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
disulfide-constrained cyclic peptide [Cyclic]
canonical L-amino-acid peptide [L]
None
None
3-16, 5-14, 7-12
Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.
Bio-Activity Profile
Antiviral Anti-HIV-1 Entry inhibition
HIV-1 196554 | JC53-BL cells
0.5 μg/mL
IC50
Mammalian: 30 h; Yeast: >20 h; E. coli: >10 h
PaperRC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. | Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI. | AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65. | DOI:10.1089/aid.2004.20.1157 | PMID:15588337 PMID15588337 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15588337/
RECORD: Rec_0421371 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
disulfide-constrained cyclic peptide [Cyclic]
canonical L-amino-acid peptide [L]
None
None
3-16, 5-14, 7-12
Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12.
Bio-Activity Profile
Antiviral Anti-HIV-1 Entry inhibition
HIV-1 HM16 | JC53-BL cells
0.6 μg/mL
IC50
Mammalian: 30 h; Yeast: >20 h; E. coli: >10 h
PaperRC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. | Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI. | AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65. | DOI:10.1089/aid.2004.20.1157 | PMID:15588337 PMID15588337 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15588337/
FIRST PREV 1 ... 4 5 6
Showing 4 records on this page · Page 6 of 6